Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05703256 · ClinicalTrials.gov registry record · NA
Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
A NA study of Major Depressive Disorder, sponsored by Kymberly Young.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT05703256: Recruiting NA study of Major Depressive Disorder, sponsored by Kymberly Young.
NCT05703256 is a NA study of Major Depressive Disorder that is actively recruiting participants, run by Kymberly Young. The registered enrollment target is 200 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05703256, a NA study of Major Depressive Disorder, is actively recruiting participants, sponsored by Kymberly Young.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as a stand-alone intervention for major depressive disorder
Primary Outcome
measures depressive symptoms. The total score will be used, which ranges from 0-63. A total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Lower values represent better outcomes.
Conditions Studied
Interventions
- DEVICE Amygdala real-time fMRI neurofeedback
- DEVICE Sham feedback
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2028-04-30 |
| Phase | NA |
What NCT05703256 shows while recruiting
NCT05703256 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Amygdala real-time fMRI neurofeedback is the first listed.
NCT05703256 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05703256 about?
NCT05703256 is a clinical study titled "Amygdala Neurofeedback for Depression - Large Scale Clinical Trial". The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as a stand-alone intervention for major depressive disorder
What is the current status of trial NCT05703256?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2023-06-01. Estimated completion is 2028-04-30.
What conditions does trial NCT05703256 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05703256?
The interventions under investigation include: Amygdala real-time fMRI neurofeedback (DEVICE), Sham feedback (DEVICE).
Who is sponsoring clinical trial NCT05703256?
This trial is sponsored by Kymberly Young, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05703256 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05703256's enrollment target sits among peer trials
200 74th of 282 higher than 203 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
-
Positive Processes and Transition to Health (PATH)
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI